Award
Delivery Order #FA460023F0086
DoD Awards $24.47M for Medical Countermeasure Development to National Strategic Research Institute
Buyer
Department of the Air Force
Award Amount
$16,194,985.00
Ceiling
$24,500,150.00
Period of Performance
Sep 01, 2023 – Aug 31, 2026
Identifier
FA460023F0086
NAICS
541715
The Department of Defense (DoD) has awarded a definitive delivery order contract valued at a potential total of $24,475,150 to the National Strategic Research Institute. This U.S. owned business focuses on medical countermeasure drug discovery and development. The contract is set to commence on September 1, 2023, and spans four years, concluding potential performance by February 28, 2028. Significant for advancing national health security, this agreement emphasizes the need for innovative medical solutions. The contract was not competed and was justified under a sole-source provision due to the specialized nature of the required services. Notably, the Board of Regents of the University of Nebraska is a key subcontractor, receiving a total of $1,142,396 for research and development activities associated with this contract. The extent of work required includes thorough research, development, and validation of medical countermeasures. The initial modification reflects a current total award value of $4,681,885.
Description
MEDICAL COUNTERMEASURE DRUG DISCOVERY AND DEVELOPMENT INCREMENT 3 SUPPORTING THE US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USA MRDC) AND THE DEFENSE HEALTH AGENCY (DCA) SEEKS TO PROVIDE THE UNITED STATES GOVERNMENT AND THE DEPARTMENT OF DEFEN